Study S001116

Obesity Treatment to Improve Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Statistical Analysis Plan (PDF)

Registration

Registration: NCT05390307
Acronym: OTID
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: COMPLETED
Enrollment: 60
Start: 2023-04-01
Primary completion: 2024-01-01
Lead sponsor: Dasman Diabetes Institute
Conditions: Type 1 Diabetes
Interventions: DRUG:Liraglutide / Semaglutide; DRUG:Dapagliflozin; DRUG:Liraglutide or Semaglutide / Dapagliflozin; DRUG:Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition; OTHER:Usual care
Results posted: FALSE

Registered primary outcomes

Weight [26 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011443	Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m2, and chronic kidney disease - A randomised, controlled pilot study. Al Ozairi E, Diabetes research and clinical practice	2026	Randomized trial	PMID 41435968 DOI	cites ClinicalTrials.gov:NCT05390307
R0018384	Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial). Al-Ozairi E, Trials	2024	Protocol	PMID 38365744 DOI	cites ClinicalTrials.gov:NCT05390307; registry reference DERIVED:38365744